- Home
- SST vs CMMB Comparison
SST vs CMMB Comparison
Compare SST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- CMMB
- Stock Information
- Founded
- SST 2013
- CMMB 2004
- Country
- SST United States
- CMMB Israel
- Employees
- SST N/A
- CMMB N/A
- Industry
- SST Diversified Commercial Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- CMMB Health Care
- Exchange
- SST Nasdaq
- CMMB Nasdaq
- Market Cap
- SST 23.3M
- CMMB 22.0M
- IPO Year
- SST N/A
- CMMB N/A
- Fundamental
- Price
- SST $5.74
- CMMB $0.94
- Analyst Decision
- SST Strong Buy
- CMMB Strong Buy
- Analyst Count
- SST 1
- CMMB 2
- Target Price
- SST $10.00
- CMMB $8.50
- AVG Volume (30 Days)
- SST 59.2K
- CMMB 127.4K
- Earning Date
- SST 08-07-2025
- CMMB 08-20-2025
- Dividend Yield
- SST N/A
- CMMB N/A
- EPS Growth
- SST N/A
- CMMB N/A
- EPS
- SST N/A
- CMMB N/A
- Revenue
- SST $317,055,000.00
- CMMB N/A
- Revenue This Year
- SST N/A
- CMMB N/A
- Revenue Next Year
- SST $8.39
- CMMB N/A
- P/E Ratio
- SST N/A
- CMMB N/A
- Revenue Growth
- SST N/A
- CMMB N/A
- 52 Week Low
- SST $2.90
- CMMB $0.87
- 52 Week High
- SST $15.30
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SST 44.70
- CMMB 19.70
- Support Level
- SST $4.95
- CMMB $0.87
- Resistance Level
- SST $6.31
- CMMB $1.01
- Average True Range (ATR)
- SST 0.70
- CMMB 0.06
- MACD
- SST -0.18
- CMMB -0.01
- Stochastic Oscillator
- SST 23.06
- CMMB 29.88
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.